- Home
- TEM vs LNTH Comparison
TEM vs LNTH Comparison
Compare TEM & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- LNTH
- Stock Information
- Founded
- TEM 2015
- LNTH 1956
- Country
- TEM United States
- LNTH United States
- Employees
- TEM N/A
- LNTH N/A
- Industry
- TEM
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TEM
- LNTH Health Care
- Exchange
- TEM NYSE
- LNTH Nasdaq
- Market Cap
- TEM 8.0B
- LNTH 7.5B
- IPO Year
- TEM 2024
- LNTH 2015
- Fundamental
- Price
- TEM $47.83
- LNTH $96.16
- Analyst Decision
- TEM Buy
- LNTH Strong Buy
- Analyst Count
- TEM 11
- LNTH 6
- Target Price
- TEM $61.22
- LNTH $129.83
- AVG Volume (30 Days)
- TEM 10.7M
- LNTH 864.1K
- Earning Date
- TEM 05-17-2025
- LNTH 05-01-2025
- Dividend Yield
- TEM N/A
- LNTH N/A
- EPS Growth
- TEM N/A
- LNTH N/A
- EPS
- TEM N/A
- LNTH 4.36
- Revenue
- TEM $693,398,000.00
- LNTH $1,533,910,000.00
- Revenue This Year
- TEM $80.13
- LNTH $6.59
- Revenue Next Year
- TEM $22.66
- LNTH $11.80
- P/E Ratio
- TEM N/A
- LNTH $22.06
- Revenue Growth
- TEM 30.38
- LNTH 18.32
- 52 Week Low
- TEM $22.89
- LNTH $58.16
- 52 Week High
- TEM $91.45
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- LNTH 48.12
- Support Level
- TEM N/A
- LNTH $94.80
- Resistance Level
- TEM N/A
- LNTH $100.73
- Average True Range (ATR)
- TEM 0.00
- LNTH 3.97
- MACD
- TEM 0.00
- LNTH -0.97
- Stochastic Oscillator
- TEM 0.00
- LNTH 8.41
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.